Tags

Type your tag names separated by a space and hit enter

A systematic review of metformin to limit weight-gain with atypical antipsychotics.
J Clin Pharm Ther. 2011 Oct; 36(5):537-45.JC

Abstract

WHAT IS KNOWN AND OBJECTIVE

Weight-gain is commonly reported in patients taking atypical antipsychotic agents. A systematic review was performed to evaluate the effectiveness of metformin for attenuation of weight-gain induced by atypical antipsychotic agents.

METHODS

A PubMed database (1966-May 2010) search was conducted, using metformin, atypical antipsychotic and weight-gain as search terms. Review articles, letters and commentaries were excluded.

RESULTS AND DISCUSSION

Thirteen trials were identified (eight randomized, double-blind, placebo-controlled trials, one crossover adult trial, one open-label uncontrolled adult trial, two open-label uncontrolled paediatric trials and one case report). Of the eight randomized, double-blind, placebo-controlled trials, three studied adult subjects and one studied children. Metformin was well tolerated. The heterogeneity of the trials did not justify meta-analytic pooling of outcomes, and we provide a best evidence synthesis.

WHAT IS NEW AND CONCLUSION

There is limited evidence for the efficacy of metformin in limiting weight-gain induced by atypical antipsychotic agents. However, the evidence is weak and further well-powered randomized, double-blind, placebo-controlled studies of longer duration should be conducted to confirm the preliminary evidence and provide better estimates of effect.

Authors+Show Affiliations

Graduate School of Clinical Pharmacy, Sookmyung Women's University, Seoul, Korea. yujeunglee@yahoo.comNo affiliation info available

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

21418264

Citation

Lee, Y J., and J H. Jeong. "A Systematic Review of Metformin to Limit Weight-gain With Atypical Antipsychotics." Journal of Clinical Pharmacy and Therapeutics, vol. 36, no. 5, 2011, pp. 537-45.
Lee YJ, Jeong JH. A systematic review of metformin to limit weight-gain with atypical antipsychotics. J Clin Pharm Ther. 2011;36(5):537-45.
Lee, Y. J., & Jeong, J. H. (2011). A systematic review of metformin to limit weight-gain with atypical antipsychotics. Journal of Clinical Pharmacy and Therapeutics, 36(5), 537-45. https://doi.org/10.1111/j.1365-2710.2011.01255.x
Lee YJ, Jeong JH. A Systematic Review of Metformin to Limit Weight-gain With Atypical Antipsychotics. J Clin Pharm Ther. 2011;36(5):537-45. PubMed PMID: 21418264.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A systematic review of metformin to limit weight-gain with atypical antipsychotics. AU - Lee,Y J, AU - Jeong,J H, Y1 - 2011/03/21/ PY - 2011/3/23/entrez PY - 2011/3/23/pubmed PY - 2012/3/9/medline SP - 537 EP - 45 JF - Journal of clinical pharmacy and therapeutics JO - J Clin Pharm Ther VL - 36 IS - 5 N2 - WHAT IS KNOWN AND OBJECTIVE: Weight-gain is commonly reported in patients taking atypical antipsychotic agents. A systematic review was performed to evaluate the effectiveness of metformin for attenuation of weight-gain induced by atypical antipsychotic agents. METHODS: A PubMed database (1966-May 2010) search was conducted, using metformin, atypical antipsychotic and weight-gain as search terms. Review articles, letters and commentaries were excluded. RESULTS AND DISCUSSION: Thirteen trials were identified (eight randomized, double-blind, placebo-controlled trials, one crossover adult trial, one open-label uncontrolled adult trial, two open-label uncontrolled paediatric trials and one case report). Of the eight randomized, double-blind, placebo-controlled trials, three studied adult subjects and one studied children. Metformin was well tolerated. The heterogeneity of the trials did not justify meta-analytic pooling of outcomes, and we provide a best evidence synthesis. WHAT IS NEW AND CONCLUSION: There is limited evidence for the efficacy of metformin in limiting weight-gain induced by atypical antipsychotic agents. However, the evidence is weak and further well-powered randomized, double-blind, placebo-controlled studies of longer duration should be conducted to confirm the preliminary evidence and provide better estimates of effect. SN - 1365-2710 UR - https://www.unboundmedicine.com/medline/citation/21418264/A_systematic_review_of_metformin_to_limit_weight_gain_with_atypical_antipsychotics_ L2 - https://doi.org/10.1111/j.1365-2710.2011.01255.x DB - PRIME DP - Unbound Medicine ER -